Compass Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 12, 2024
CMPX$0.76+10.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Compass Therapeutics, Inc. | ||
| Date: August 12, 2024 | By: | /s/ Thomas Schuetz |
|---|---|---|
| Thomas Schuetz, MD | ||
| Principal Executive Officer, Principal Financial and Accounting Officer | ||
| Date: August 12, 2024 | By: | /s/ Neil Lerner |
| Neil Lerner, CPA | ||
| Vice President - Finance | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.